{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:33:42Z","timestamp":1778600022967,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.mcna.2010.04.004","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T00:47:47Z","timestamp":1277081267000},"page":"727-742","source":"Crossref","is-referenced-by-count":38,"title":["Severe Cutaneous Adverse Reactions: Acute Generalized Exanthematous Pustulosis, Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome"],"prefix":"10.1016","volume":"94","author":[{"given":"Thomas","family":"Harr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2010.04.004_bib1","first-page":"37","volume":"107","author":"Beylot","year":"1980","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.mcna.2010.04.004_bib2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2133.1968.tb11947.x","article-title":"Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases","volume":"80","author":"Baker","year":"1968","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib3","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2133.2005.06393.x","article-title":"Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature","volume":"152","author":"Beltraminelli","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-4632.2009.03908.x","article-title":"Acute generalized exanthematous pustulosis: report of 12 cases and literature review","volume":"48","author":"Guevara-Gutierrez","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib5","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1046\/j.1365-2230.2000.00729.x","article-title":"Acute generalized exanthematous pustulosis associated with polysensitivity to paracetamol and bromhexine: the diagnostic role of in vitro interferon-gamma release test","volume":"25","author":"Halevy","year":"2000","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.clinthera.2008.05.014","article-title":"Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature","volume":"30","author":"Paradisi","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.mcna.2010.04.004_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2014a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.mcna.2010.04.004_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2133.1956.tb12774.x","article-title":"Subcorneal pustular dermatosis","volume":"68","author":"Sneddon","year":"1956","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00130832-200208000-00006","article-title":"Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells","volume":"2","author":"Britschgi","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.mcna.2010.04.004_bib11","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1172\/JCI12118","article-title":"T-cell involvement in drug-induced acute generalized exanthematous pustulosis","volume":"107","author":"Britschgi","year":"2001","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.mcna.2010.04.004_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.mcna.2010.04.004_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-0438","article-title":"Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia","volume":"88","author":"Chang","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.mcna.2010.04.004_bib14","first-page":"410","article-title":"Profile of acute generalized exanthematous pustulosis in Israel during 2002\u20132005: results of the RegiSCAR Study","volume":"10","author":"Davidovici","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.mcna.2010.04.004_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.0105-1873.2004.00366.x","article-title":"Systemically induced allergic exanthem from mercury","volume":"50","author":"Lerch","year":"2004","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.mcna.2010.04.004_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaad.2006.05.010","article-title":"Acute generalized exanthematous pustulosis following a spider bite: report of 3 cases","volume":"55","author":"Davidovici","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib19","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2010.04.004_bib20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/00002018-200528100-00008","article-title":"Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors","volume":"28","author":"La Grenade","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.mcna.2010.04.004_bib21","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2010.04.004_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/B:NEON.0000014538.31561.bc","article-title":"Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider","volume":"66","author":"Aguiar","year":"2004","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.mcna.2010.04.004_bib23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1468-3083.2006.01510.x","article-title":"Stevens-Johnson syndrome in two patients treated with cranial irradiation and phenytoin","volume":"20","author":"Aydin","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.mcna.2010.04.004_bib24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.mcna.2010.04.004_bib25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.mcna.2010.04.004_bib26","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.mcna.2010.04.004_bib27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.mcna.2010.04.004_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A\u00a0European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.mcna.2010.04.004_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A\u00a0marker for Stevens-Johnson syndrome: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.mcna.2010.04.004_bib30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.mcna.2010.04.004_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.129.1.92","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000070938","article-title":"Dermatological and ophthalmological sequels in toxic epidermal necrolysis","volume":"207","author":"Magina","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.mcna.2010.04.004_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.bcr.0000194268.01514.f8","article-title":"Long-term follow-up of patients treated for toxic epidermal necrolysis","volume":"27","author":"Oplatek","year":"2006","journal-title":"J\u00a0Burn Care Res"},{"key":"10.1016\/j.mcna.2010.04.004_bib34","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.mcna.2010.04.004_bib35","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.mcna.2010.04.004_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.mcna.2010.04.004_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib39","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.mcna.2010.04.004_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006454-200102000-00022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system","volume":"20","author":"Ball","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.mcna.2010.04.004_bib41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1212\/WNL.49.2.542","article-title":"Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study","volume":"49","author":"Tennis","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2010.04.004_bib42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A\u00a0multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.mcna.2010.04.004_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2340\/00015555-0249","article-title":"Intravenous immunoglobulin: properties, mode of action and practical use in dermatology","volume":"87","author":"Prins","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.mcna.2010.04.004_bib46","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.mcna.2010.04.004_bib48","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.mcna.2010.04.004_bib49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib51","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J\u00a0Burn Care Rehabil"},{"key":"10.1016\/j.mcna.2010.04.004_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2005.tb00704.x","article-title":"High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series","volume":"32","author":"Tan","year":"2005","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib54","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/0378-6323.18943","article-title":"Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study","volume":"71","author":"Mangla","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.mcna.2010.04.004_bib55","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.mcna.2010.04.004_bib56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/00015550310005906","article-title":"Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate","volume":"84","author":"Hashim","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.mcna.2010.04.004_bib57","first-page":"31","article-title":"Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF","volume":"32","author":"Robak","year":"2001","journal-title":"J\u00a0Med"},{"key":"10.1016\/j.mcna.2010.04.004_bib58","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.109.1.74","article-title":"Long-term consequences of toxic epidermal necrolysis in children","volume":"109","author":"Sheridan","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.mcna.2010.04.004_bib59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ophtha.2008.12.048","article-title":"Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications","volume":"116","author":"Sotozono","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mcna.2010.04.004_bib60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.mcna.2010.04.004_bib61","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0536.1996.tb02364.x","article-title":"Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"35","author":"Wolkenstein","year":"1996","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.mcna.2010.04.004_bib62","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1398-9995.2007.01553.x","article-title":"Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption","volume":"62","author":"Kano","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.mcna.2010.04.004_bib63","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2009.02180.x","article-title":"In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases","volume":"65","author":"Zawodniak","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.mcna.2010.04.004_bib64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712510000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712510000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T17:22:56Z","timestamp":1685640176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712510000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0025712510000568"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2010.04.004","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}